Cognitive impairment affects 50-70% of Multiple Sclerosis (MS) patients and is noted as one of the most disabling aspects of the disease. Worsening cognitive processing speed impacts patients’ quality of life as simple tasks become more difficult.
Addressing cognitive impairment and decline is vital in the development of MS treatments. Cogstate supports sponsors in these efforts by providing highly sensitive and reliable computerized cognitive testing, as well as support for conventional assessments, such as the Brief International Cognitive Assessment for MS (BICAMS).
Download the fact sheet below to learn more about we support MS clinical trials globally.